Literature DB >> 15548541

Crystal structure of thrombin bound to heparin.

Wendy J Carter1, Evis Cama, James A Huntington.   

Abstract

Thrombin is the final protease in the blood coagulation cascade and serves both pro- and anticoagulant functions through the cleavage of several targets. The ability of thrombin to specifically recognize a wide range of substrates derives from interactions that occur outside of the active site of thrombin. Thrombin possesses two anion binding exosites, which mediate many of its interactions with cofactors and substrates, and although many structures of thrombin have been solved, few such interactions have been described in molecular detail. Glycosaminoglycan binding to exosite II of thrombin plays a major role in switching off the procoagulant functions of thrombin by mediating its irreversible inhibition by circulating serpins and by its binding to the endothelial cell surface receptor thrombomodulin. Here we report the 1.85-A structure of human alpha-thrombin bound to a heparin fragment of eight monosaccharide units in length. The asymmetric unit is composed of two thrombin dimers, each sharing a single heparin octasaccharide chain. The observed interactions are fully consistent with previous mutagenesis studies and illustrate on a molecular level the cofactor interaction that is critical for the restriction of clotting to the site of blood vessel injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548541     DOI: 10.1074/jbc.M411606200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

2.  Crystal structure of an RNA aptamer bound to thrombin.

Authors:  Stephen B Long; Meredith B Long; Rebekah R White; Bruce A Sullenger
Journal:  RNA       Date:  2008-10-29       Impact factor: 4.942

3.  Investigation of the heparin-thrombin interaction by dynamic force spectroscopy.

Authors:  Congzhou Wang; Yingzi Jin; Umesh R Desai; Vamsi K Yadavalli
Journal:  Biochim Biophys Acta       Date:  2015-01-31

4.  Long range communication between exosites 1 and 2 modulates thrombin function.

Authors:  Nicolas S Petrera; Alan R Stafford; Beverly A Leslie; Colin A Kretz; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2009-07-09       Impact factor: 5.157

5.  The role of thrombin exosites I and II in the activation of human coagulation factor V.

Authors:  Kenneth Segers; Björn Dahlbäck; Paul E Bock; Guido Tans; Jan Rosing; Gerry A F Nicolaes
Journal:  J Biol Chem       Date:  2007-09-18       Impact factor: 5.157

6.  Polyphosphate binds with high affinity to exosite II of thrombin.

Authors:  N J Mutch; T Myles; L L K Leung; J H Morrissey
Journal:  J Thromb Haemost       Date:  2009-12-11       Impact factor: 5.824

7.  Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.

Authors:  Daniel J D Johnson; Jonathan Langdown; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  Na+ binding to meizothrombin desF1.

Authors:  M E Papaconstantinou; P S Gandhi; Z Chen; A Bah; E Di Cera
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

Review 9.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

10.  Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.

Authors:  Joyce N Gonzales; Kyung-mi Kim; Marina A Zemskova; Ruslan Rafikov; Brenten Heeke; Matthew N Varn; Stephen Black; Thomas P Kennedy; Alexander D Verin; Evgeny A Zemskov
Journal:  Vascul Pharmacol       Date:  2014-01-25       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.